ArticleOncotarget2018
The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Translating Fibrosis to Malignancy: Biomarkers and Therapeutic Opportunities in Liver Fibrosis and Hepatocellular Carcinoma.Medical sciences (Basel, Switzerland) · 2026Review
- [Chinese expert consensus on the use of standardized second-line drugs for primary hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Activation of lymphangiogenesis by platelet as novel therapeutic approaches for liver cirrhosis and portal hypertension.World journal of gastroenterology · 2025Article
- Decoding Hepatocellular Carcinoma Metastasis: Molecular Mechanisms, Targeted Therapies, and Potential Biomarkers.Current issues in molecular biology · 2025Review
- Platelet activation relieves liver portal hypertensionWorld journal of gastroenterology · 2025Article
- From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.Metabolites · 2025Review
- Chinese expert consensus on refined diagnosis, treatment, and management of advanced primary liver cancer (2023 edition).Liver research (Beijing, China) · 2024Article
- Review
- [Expert consensus on precise diagnosis and management of primary hepatocellular carcinoma in advanced stage (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Emerging Therapeutic Targets for Portal Hypertension.Current hepatology reports · 2023Review
- Recent therapeutics in hepatocellular carcinoma.American journal of cancer research · 2023Review
- Current and investigational drugs in early clinical development for portal hypertension.Frontiers in medicine · 2022Review
- The Role of von Willebrand Factor Antigen in Predicting Survival of Patients with HBV-Related Cirrhosis.Canadian journal of gastroenterology & hepatology · 2022Article
- New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation.Drug design, development and therapy · 2022Article
- Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.JHEP reports : innovation in hepatology · 2021Review
- Experience with regorafenib in the treatment of hepatocellular carcinoma.Therapeutic advances in gastroenterology · 2021Review
- Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.Journal of hepatocellular carcinoma · 2021Review
- Targeted therapy for hepatocellular carcinoma.Signal transduction and targeted therapy · 2020Review
- Article
- Regorafenib in patients with recurrent high-grade astrocytoma.Journal of cancer research and clinical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAngiogenesis is critically involved in the development of liver fibrosis, portal hypertension (PHT) and hepatocellular carcinoma (HCC). Regorafenib is a novel second-line therapy for HCC, but might also be beneficial in fibrosis and PHT even in absence of HCC. This study investigated the effects of regorafenib in experimental models without HCC.
methodsFibrosis (
resultsLong-term treatment with regorafenib improved portal hypertension most likely due to blunted angiogenesis, without affecting fibrosis progression or regression. Interestingly, acute administration of regorafenib also ameliorated portal hemodynamics. Although regorafenib treatment led to hepatotoxic side effects in long-term treated fibrotic animals, in partial portal vein ligated rats, no liver toxicity due to regorafenib was observed. DISCUSSION: Regorafenib might be especially suitable as therapy in patients with PHT and preserved liver function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.